UiPath (NYSE:PATH) Trading Up 1.7%

UiPath Inc. (NYSE:PATH - Get Free Report)'s share price rose 1.7% during trading on Wednesday . The company traded as high as $20.95 and last traded at $20.55. Approximately 2,258,779 shares traded hands during trading, a decline of 72% from the average daily volume of 8,168,117 shares. The stock had previously closed at $20.20.

Analyst Ratings Changes

PATH has been the subject of a number of analyst reports. Barclays lifted their price objective on UiPath from $23.00 to $25.00 and gave the stock an "equal weight" rating in a research note on Friday, March 15th. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 price objective on shares of UiPath in a research report on Wednesday, March 20th. Royal Bank of Canada restated a "sector perform" rating and set a $29.00 price objective on shares of UiPath in a report on Monday, April 1st. Mizuho lifted their target price on UiPath from $22.00 to $25.00 and gave the company a "neutral" rating in a research report on Thursday, March 14th. Finally, Bank of America boosted their price objective on shares of UiPath from $26.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $27.41.

UiPath Price Performance

The business has a 50-day simple moving average of $21.23 and a two-hundred day simple moving average of $21.93. The stock has a market cap of $11.80 billion, a price-to-earnings ratio of -121.99 and a beta of 1.01.

UiPath (NYSE:PATH - Get Free Report) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. As a group, equities analysts anticipate that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Ashim Gupta sold 16,000 shares of the business's stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the completion of the sale, the chief financial officer now directly owns 87,505 shares in the company, valued at $1,998,614.20. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 96,000 shares of company stock valued at $2,023,440. 22.37% of the stock is owned by insiders.

Institutional Investors Weigh In On UiPath

Several institutional investors have recently made changes to their positions in the stock. Mark Sheptoff Financial Planning LLC bought a new stake in UiPath during the fourth quarter worth $25,000. HighMark Wealth Management LLC bought a new stake in UiPath during the fourth quarter worth $27,000. Cypress Capital Management LLC WY bought a new stake in UiPath during the fourth quarter worth $29,000. ORG Partners LLC lifted its stake in UiPath by 875.6% during the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company's stock worth $27,000 after purchasing an additional 1,112 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in UiPath during the fourth quarter worth $36,000. 62.50% of the stock is currently owned by institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.